Literature DB >> 6978338

Human histocompatibility antigen mutants immunoselected in vitro. Biochemical analysis of a mutant which synthesizes an altered HLA-A2 heavy chain.

M S Krangel, D Pious, J L Strominger.   

Abstract

Immunoselection with HLA-A2 or HLA-A1 specific alloantisera has been utilized to isolate spontaneously arising and mutagen-induced variants from the B lymphoblastoid cell line T5-1 (HLA haplotypes DR3, B8, A1 and DR1, B27, Cw1, A2). Such variants are characterized by reduced reactivity with alloantisera of the selecting specificity, but normal reactivity with alloantisera directed to the other HLA specificities of T5-1. Biochemical analysis reveals two classes of variants. In all HLA-A1 and some HLA-A2 variants, the heavy chain in question cannot be detected; however, in other HLA-A2 variants, a structurally altered HLA-A2 heavy chain is found. In the HLA-A2 variant 6.6.5, this heavy chain is glycosylated and thus has presumably been inserted into the rough endoplasmic reticulum membrane in vivo. However, unlike all other HLA heavy chains, the 6.6.5 HLA-A2 heavy chain does not associate with beta 2-microglobulin, does not undergo processing of its high mannose oligosaccharide, and does not migrate to the cell surface, although it is relatively stably expressed within the cell. We suggest that the primary defect in these cells is the failure of the 6.6.5 HLA-A2 heavy chain to associate stably with beta 2-microglobulin. It is likely that the observed structural alteration in this heavy chain reflects a change in amino acid sequence, and thus, a mutation in the structural gene encoding HLA-A2.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978338

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Functional evaluation of CD19- and CD22-negative variants of B-lymphoid cell lines.

Authors:  S Kiesel; A Pezzutto; R Haas; G Moldenhauer; B Dörken
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

2.  Refinement of HLA gene mapping with induced B-cell line mutants.

Authors:  B Spring; C Fonatsch; C Müller; G Pawelec; J Kömpf; P Wernet; A Ziegler
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

Review 3.  Somatic cell variants of the murine major histocompatibility complex.

Authors:  R A Zeff; P A Kumar; H Mashimo; M Nakagawa; B McCue; F Borriello; K Kesari; J Geliebter; S Hemmi; G Pfaffenbach
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

Review 4.  Cell-surface-antigen mutants of haematopoietic cells. Tools to study differentiation, biosynthesis and function.

Authors:  R Hyman
Journal:  Biochem J       Date:  1985-01-01       Impact factor: 3.857

Review 5.  Mutations that influence the secretory path in animal cells.

Authors:  A M Tartakoff
Journal:  Biochem J       Date:  1983-10-15       Impact factor: 3.857

6.  Synthesis of beta-hexosaminidase in cell-free translation and in intact fibroblasts: an insoluble precursor alpha chain in a rare form of Tay-Sachs disease.

Authors:  R L Proia; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

7.  Measurements of the frequency of human erythrocytes with gene expression loss phenotypes at the glycophorin A locus.

Authors:  R G Langlois; W L Bigbee; R H Jensen
Journal:  Hum Genet       Date:  1986-12       Impact factor: 4.132

8.  High-level expression of a cloned HLA heavy chain gene introduced into mouse cells on a bovine papillomavirus vector.

Authors:  D DiMaio; V Corbin; E Sibley; T Maniatis
Journal:  Mol Cell Biol       Date:  1984-02       Impact factor: 4.272

9.  HLA antigen structural gene mutants selected with an allospecific monoclonal antibody.

Authors:  D Pious; M S Krangel; L L Dixon; P Parham; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

10.  HLA-A2 mutants immunoselected in vitro. Definition of residues contributing to an HLA-A2-specific serological determinant.

Authors:  M S Krangel; S Taketani; D Pious; J L Strominger
Journal:  J Exp Med       Date:  1983-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.